DDPP tumor/normal intensity plots profiles of differential gene expression of the everolimus key genes for the six patients treated with everolimus in monotherapy. Clinical outcome is described in Table 1. a ID 090, head and neck carcinoma, PFS = 1.3 months (progressive disease), third therapy line. b ID 227, liposarcoma, PFS = 1.7 months (progressive disease) in fifth therapy line. c ID 117, head and neck carcinoma, PFS = 1.9 months (progressive disease), third therapy line. d ID 006, unknown primary origin, PFS = 8.1 months (stable disease) in second therapy line. e ID 148, neuroendocrine tumor of small gut PFS = 11.6 months (stable disease) in third therapy line. f ID 203, neuroendocrine tumor of small intestine, PFS = 60+ months (partial response disease) in second therapy line. Y axis: intensity of the expression in tumors, X axis: intensity of the expression in normal matched tissue. Intensities are measured as relative fluorescence unit (RFU) signal as assessed with Agilent microarray technology. Overexpression for a given mRNA in the tumor as compared to the normal is denoted in red points, underexpression is denoted in green, and no change is denoted in black. Data source WINTHER trial10.